Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.
Open Access
- 1 June 1989
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 13 (6_pt_2), 948-953
- https://doi.org/10.1161/01.hyp.13.6.948
Abstract
Hemodynamic and biochemical effects of the new renin inhibitor CGP 38560A (molecular weight 826) were tested in 15 healthy volunteers after a single-blind, randomized, placebo-controlled protocol. At a 2-week interval, groups of five subjects received a 30-minute infusion of either 5% dextrose or CGP 38560A 50, 125, or 250 micrograms/kg. Blood pressure, heart rate, plasma renin activity, active and total renin, angiotensin-(1-8)octapeptide (angiotensin II), and aldosterone were sequentially measured up to 3 hours from the onset of the infusion. There was no consistent change in blood pressure or heart rate. Plasma renin activity and angiotensin II decreased dose dependently, and peak suppression was observed at the end of the infusion of CGP 38560A and after the 250-micrograms/kg dose. Plasma renin activity fell from 1.0 +/- 0.19 (mean +/- SEM) to less than 0.05 ng/ml/hr in all five subjects (p less than 0.001), and angiotensin II fell from 7.7 +/- 1.2 to 2.6 +/- 0.9 femtomole/ml (p less than 0.01). Active renin rose fourfold from 24 +/- 1.9 to 98 +/- 14 pg/ml (p less than 0.001) at the end of the infusion of the high dose. Plasma angiotensin II returned toward its initial values much faster than plasma renin activity and active renin. In conclusion, CGP 38560A was well tolerated. It induced a dose-dependent decrease in angiotensin II and plasma renin activity and a long-lasting and dose-dependent rise in active renin. The doses used did not reduce plasma angiotensin II maximally despite reduction of plasma renin activity to unmeasurable levels.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 12 references indexed in Scilit:
- Synthesis and biological activity of some transition-state inhibitors of human reninJournal of Medicinal Chemistry, 1988
- Plasma Angiotensin-(1-8) Octapeptide Measurement to Assess Acute Angiotensin-Converting Enzyme Inhibition with Captopril Administered Parenterally to Normal SubjectsJournal of Cardiovascular Pharmacology, 1988
- Rapid Measurement of Total and Active Renin: Plasma Concentrations During Acute and Sustained Converting Enzyme Inhibition with CGS 14824AClinical and Experimental Hypertension. Part A: Theory and Practice, 1987
- Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal VolunteersJournal of Cardiovascular Pharmacology, 1987
- A Study of the Renin Inhibitor H142 in ManJournal Of Hypertension, 1985
- Increased plasma renin during renin inhibition. Studies with a novel immunoassay.Hypertension, 1985
- True versus immunoreactive angiotensin II in human plasma.Hypertension, 1985
- Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs.Hypertension, 1984
- Potent new inhibitors of human reninNature, 1982
- Disappearance Rate of Endogenous Renin from the Plasma After Bilateral Nephrectomy in HumansJournal of Clinical Endocrinology & Metabolism, 1969